Monographie - Diazepam - Stabilis 4.0

Utolsó frissítés :
19/11/2024

Diazepam

Kémiai szerkezet

Kereskedelmi név

A kereskedelmi név meghatározó jelentőségű: a készítmények összetétele országonként, előállítóként eltérő lehet

Ansiolin	Olaszország
Bamyl	Chile
Compaz	Brazília
Daiv	Argentína, Colombia
Diactal	Argentína
Diapam	Finnország, Törökország
Diazem	Törökország
Diazemuls	Hollandia, Kanada, Nagy-Britannia, Olaszország
Diazep	Németország
Diazepam	Ausztrália, Colombia, Ecuador, Kanada, Németország
Faustan	Németország
Gewalcalm	Ausztria
Kiatrium	Brazília
Noan	Olaszország
Normabel	Horvátország
Ortopsique	Ecuador
Pacitran	Peru
Pax	Dél-Afrikai Köztársaság
Relanium	Lengyelország
Rupediz	Argentína
Stedon	Görögország
Stesolid	Dánia, Izland, Németország, Norvégia, Svájc, Svédország, Szaúd-Arábiában
Sunzepan	Mexikó
Tranject	Dél-Afrikai Köztársaság
Valium	Ausztria, Belgium, Brazília, Colombia, Dél-Afrikai Köztársaság, Ecuador, Egyesült Arab Emírségek, Egyiptom, Franciaország, Hollandia, Luxemburg, Marokkó, Mexikó, Németország, Olaszország, Portugália, Spanyolország, Svájc, Szaúd-Arábiában, Venezuela

Irodalom : Diazepam

	Type	publikáció
55	Napló	Smith A, Bird G. The compatibility of diazepam with infusion fluids and their containers. J Clin Hosp Pharm 1982 ; 7: 181-186.
58	Napló	Parker WA. Physical compatibility of ranitidine HCl with preoperative injectable medications. Can J Hosp Pharm 1985 ; 38: 160-161.
59	Napló	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Napló	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
93	Napló	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
190	Napló	Lee MG. Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets. Am J Hosp Pharm 1986 ; 43: 1945-1950.
198	Napló	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
226	Napló	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.
266	Napló	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299	Napló	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Napló	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
348	Napló	Hancock BG, Black CD. Effect of a polyethylene-lined administration set on the avaibility of diazepam injection. Am J Hosp Pharm 1985 ; 42: 335-339.
350	Napló	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
351	Napló	Yliruusi JK, Uotila JA, Kristoffersson ER. Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems. Am J Hosp Pharm 1986 ; 43: 2795-2799.
352	Napló	Yliruusi JK, Uotilo JA, Kristoffersson ER. Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets. Am J Hosp Pharm 1986 ; 43: 2789-2794.
402	Napló	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
476	Napló	Knapp AJ, Mauro VF, Alexander KS. Incompatibility of ketorolac tromethamine with selected postoperative drugs. Am J Hosp Pharm 1992 ; 49: 2960-2962.
496	Napló	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
616	Napló	Jump WG, Plaza VM, Poremba A. Compatibility of nalbuphine hydrochloride with other preoperative medications. Am J Hosp Pharm 1982 ; 39: 841-843.
621	Napló	Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER. Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers. Am J Hosp Pharm 1982 ; 39: 1018-1021.
660	Napló	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
711	Napló	Cloyd JC, Vezeau C, Miller KW. Avaibility of diazepam from plastic containers. Am J Hosp Pharm 1980 ; 37: 492-496.
712	Napló	Parker WA, MacCara ME. Compatibility of diazepam with intravenous fluid containers and administration sets. Am J Hosp Pharm 1980 ; 37: 496-500.
730	Napló	Allen LV, Saul Levinson R, Phisutsinthop D. Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets. Am J Hosp Pharm 1977 ; 34: 939-943.
731	Napló	Morris ME. Compatibility and stability of diazepam injection following dilution with intravenous fluids. Am J Hosp Pharm 1978 ; 35: 669-672.
921	Napló	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Napló	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1041	Napló	Hasegawa GR, Eder JF. Visual compatibility of dobutamine hydrochloride with other injectable drugs. Am J Hosp Pharm 1984 ; 41: 949-951.
1057	Napló	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1067	Napló	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1102	Napló	Cossum PA, Roberts MS. Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems. Eur J Clin Pharmacol 1981 ; 19: 181-185.
1173	Napló	Kowaluk EA, Roberts MS, Blackburn HD, Polack AE. Interactions between drugs and polyvinyl chloride infusion bags. Am J Hosp Pharm 1981 ; 38: 1308-1314.
1182	Napló	Mason NA, Cline S, Hyneck ML, Berardi RR, Ho NFH, Flynn GL. Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. Am J Hosp Pharm 1981 ; 38: 1449-1454.
1199	Napló	Smith FM, Nuessle NO. Stability of diazepam injection repackaged in glass unit-dose syringes. Am J Hosp Pharm 1982 ; 1687-1690.
1200	Napló	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1232	Napló	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1269	Napló	DeMuynck C, De Vroe C, Remon JP, Colardyn F. Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units. J Clin Pharm Ther 1988 ; 13: 335-340.
1271	Napló	Mathot F, Bonnard J, Paris P, Bosly J. Reliable continuous IV perfusion system for diazepam. J Pharm Belg 1982 ; 37: 153-156.
1366	Napló	Jeglum EL, Winter E, Kotos M. Nafcillin sodium incompatibility with acidic solutions. Am J Hosp Pharm 1981 ; 38: 462,464.
1424	Napló	Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK. Prehospital stability of diazepam and lorazepam. Am J Emerg Med 1999 ; 17: 333-337.
1438	Napló	Souney PF, Solomon MA, Stancher D. Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications. Am J Hosp Pharm 1984 ; 41: 1840-1841.
1472	Napló	Salomies HEM, Heinonen RM, Toppila MAI. Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags). Int J Pharm 1994 ; 110: 197-201.
1512	Laboratórium	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1522	Laboratórium	Macoflex N® Maco Pharma 2001
1603	Napló	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1625	Napló	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Napló	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Napló	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Napló	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Napló	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	Napló	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Napló	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1960	Napló	Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C. Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers. J Pharm Biomed Anal 2005 ; 37: 259-264.
1974	Napló	Chandler SW, Trissel LA, Weinstein SM Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2087	Napló	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Napló	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2262	Napló	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Napló	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2324	Napló	Treleano A, Wolz G, Brandsch R, Welle F. Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application Int J Pharm 2009 ; 369, 1-2 : 30-37
3012	Napló	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3184	Laboratórium	Hyaluronidase (Hyalase®) - Summary of Product characteristics. CP Pharmaceuticals 2005
3216	Napló	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Napló	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3332	Laboratórium	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3408	Napló	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3474	Laboratórium	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3501	Laboratórium	Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics Pfizer 2011
3521	Laboratórium	Tramadol® - Summary of Product Characteristics. Beacon Pharmaceuticals 2012
3539	Laboratórium	Bivalirudin (Angiox®) - Summary of Product Characteristics. The Medecines Company 2013
3540	Laboratórium	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3560	Laboratórium	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3564	Laboratórium	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Napló	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3599	Laboratórium	Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics Amco Amdipharm Mercry 2013
3607	Laboratórium	Esmolol hydrochloride for injection - Summary of Product Characteristics AOP Orphan Pharmaceuticals AG 2013
3614	Laboratórium	Nicardipine Injection - Summary of Product Characteristics American Regent Inc 2013
3617	Laboratórium	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3672	Laboratórium	Nalbuphine Mylan - Résumé des caractéristiques du produit Mylan SAS 2016
3766	Napló	Forrest J.M, Hildgen P. Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Napló	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	Napló	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3885	Napló	Su-Eon Jin, Siwon You, Seungho Jeon, Sung-Joo Hwang. Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method. Int J Pharm 2016 ; 506 : 414-419.
3932	Laboratórium	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3941	Laboratórium	Nicardipine - Summary of Product Characteristics Concordia International 2017
3964	Napló	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4154	Laboratórium	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4319	Napló	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4428	Napló	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4435	Napló	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4603	Napló	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratórium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4700	Laboratórium	Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics AS Kalceks 2022
4742	Napló	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales